Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Alexion Pharmaceuticals, Inc.
WARNING LETTER
•Alexion Pharmaceuticals, Inc.•August 6, 2012

Alexion Pharmaceuticals, Inc. – FDA Warning Letter, Aug 6, 2012

Record Details

On March 22, 2013, the FDA issued a Warning Letter to Alexion Pharmaceuticals, Inc. following a July-August 2012 inspection of their Smithfield, RI facility. The inspection revealed significant Current Good Manufacturing Practice (CGMP) violations in the manufacture of Soliris API, rendering the API adulterated.

Key violations included: 1. **Inadequate investigation of critical deviations:** Six Soliris API lots were contaminated with *Bacillus thuringiensis* (TNTC/10 mL), exceeding action limits. *Acinetobacter radioresistens* was also found in one lot. The firm failed to conduct thorough root cause investigations, assess the impact of contamination on the final product, or verify cleaning effectiveness. Reliance on additional testing without scientific rationale for clearance of non-host cell impurities was noted. The toxicology assessment for pediatric use was questioned. 2. **Quality unit failure:** The quality unit released two Soliris API lots (TNTC/10mL contamination) for further manufacturing without adequate scientific justification, with inconsistent actions taken for each lot. Repeated bioreactor cleaning cycles indicated potential design or function issues.

The FDA noted a lack of a robust quality system, with repeat citations from a February 2011 inspection. The agency recommended engaging a third-party CGMP consultant. Alexion was instructed to provide a written response within fifteen working days detailing corrective actions and timelines. Failure to comply could result in legal action

Company
Alexion Pharmaceuticals, Inc.
Inspection date
August 6, 2012
Product type
Drugs
Office
New England District Office
People
  • Mutahar Shamsi (District Director)
  • Scott C. Nickerson
View Company Profile

ID · 87338350-6bc1-4400-affa-2b9ced0020aa

Violation Codes3
21 U.S.C. 351(a)(2)(B)FD&C Act 501(a)(2)(B)21 U.S.C. 356C(a)(1)

Full citation text and observation details available on the Dashboard.

Other documents for Alexion Pharmaceuticals, Inc.
  • 483 - 2025-03-07March 7, 2025
  • 483 - 2024-11-07November 7, 2024

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Alexion Pharmaceuticals, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.